Go to the App Stor or Google Play on your mobile device and search 'MyCHOP': If you don’t have a MyCHOP account, please call the front desk of your provider’s office and ask to enroll in MyCHOP. If you have a MyCHOP account, sign in on the right to make sure your account is still active. If you have any issues with your account, use the. Commuter Transit Account. A WageWorks® Commuter Transit Account is a pre-tax benefit account used to pay for public transit—including train, subway, bus, ferry or vanpool—as part of your daily commute. Chop Commute lets you take the guess work out of your daily commute by seeing real-time traffic and drive times specific to your route right on your Mac menu bar (system status tray).
At Children’s Hospital of Philadelphia, trust is the foundation of our relationship with you, our patients and families.
Keeping Patients Safe
After much preparation throughout the COVID-19 pandemic, we are gradually and carefully resuming more in-person visits at our Main Campus and our Care Network locations. We have many precautions in place to keep you and your child safe.
Here's what you can expect when you come back to see usGet the MyCHOP Mobile App
Download the MyCHOP mobile app for access to more tools to help manage your child’s care, including telehealth options. Go to the App Stor or Google Play on your mobile device and search 'MyCHOP':
- If you don’t have a MyCHOP account, please call the front desk of your provider’s office and ask to enroll in MyCHOP.
- If you have a MyCHOP account, sign in on the right to make sure your account is still active. If you have any issues with your account, use the chat feature or request MyCHOP support here.
Communicate with your doctor
Get answers to your medical questions from the comfort of your own homeAccess your test results
No more waiting for a phone call or letter – view your results and your doctor's comments within daysRequest prescription refills
Send a refill request for any of your refillable medicationsManage your appointments
Schedule your next appointment, access video visits, view details of your past and upcoming appointmentsEstimate
Get Estimates for Services
Click here for Frequently Asked Questions (FAQs)
CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of:
- Cyclophosphamide, an alkylating agent which damages DNA by binding to it and causing the formation of cross-links
- Hydroxydaunorubicin (also called doxorubicin or adriamycin), an intercalating agent which damages DNA by inserting itself between DNA bases
- Oncovin (vincristine), which prevents cells from duplicating by binding to the protein tubulin
- Prednisone or Prednisolone, which are corticosteroids.
Sometimes the chimeric anti-CD20 monoclonal antibody, rituximab, is added to this treatment regimen to form the R-CHOP regimen.
Dosing regimen[edit]
Drug | Standard [R]-CHOP-14 or [R]-CHOP-21 | [R]-Maxi-CHOP | Mode | Days |
---|---|---|---|---|
(R)ituximab | 375 mg/m2 | 375 mg/m2 | IV infusion | Day 1 |
(C)yclophosphamide | 750 mg/m2 | 1200 mg/m2 | IV infusion | Day 1 |
(H)ydroxydaunorubicin | 50 mg/m2 | 75 mg/m2 | IV bolus | Day 1 |
(O)ncovin | 1.4 mg/m2 (max. 2 mg) | 2 mg | IV bolus | Day 1 |
(P)rednisone or (P)rednisolone | 40 mg/m2 | 100 mg | PO qd | Days 1-5 |
R-Maxi-CHOP is used in mantle cell lymphoma and is given in 21-day intervals, alternating with R-HDAC (rituximab + high-dose cytarabine).[1]
In most other non-Hodgkin lymphomas (excluding some aggressive forms), standard-dose [R]-CHOP is generally used as first-line therapy.
Uses and indications[edit]
Normal cells are more able than cancer cells to repair damage from chemotherapy drugs.
This regimen can also be combined with the monoclonal antibodyrituximab if the lymphoma is of B cell origin; this combination is called R-CHOP. Typically, courses are administered at an interval of two or three weeks (CHOP-14 and CHOP-21 respectively). A stagingCT scan is generally performed after three cycles to assess whether the disease is responding to treatment.
In patients with a history of cardiovascular disease, doxorubicin (which is cardiotoxic) is often deemed to be too great a risk and is omitted from the regimen. The combination is then referred to as COP (cyclophosphamide, Oncovin, and prednisone or prednisolone) or CVP (cyclophosphamide, vincristine, and prednisone or prednisolone).
Side-effects and complications[edit]
The combination is generally well tolerated.[2]Chemotherapy-induced nausea and vomiting may require antiemetics (such as ondansetron), and hemorrhagic cystitis is prevented with administration of mesna. Alopecia (hair loss) is common.
Chop Commute Meaning
Neutropenia generally develops in the second week. During this period, many clinicians recommend pegfilgrastim or prophylactic use of ciprofloxacin.[1] If a fever develops in the neutropenic period, urgent medical assessment is required for neutropenic sepsis, as infections in patients with low neutrophil counts may progress rapidly.
Allopurinol is typically co-administered prophylactically to prevent hyperuricemia that results from tumor lysis syndrome, the result of rapid death of tumor cells.
History[edit]
A pivotal study published in 1993 compared CHOP to several other chemotherapy regimens (e.g. m-BACOD, ProMACE-CytaBOM, MACOP-B) for advanced non-Hodgkin's lymphoma.[2] CHOP emerged as the regimen with the least toxicity but similar efficacy.
Chop Commute Employee
However, in Germany in 2012, bendamustine has displaced [R-]CHOP to become the first line treatment of choice for indolent lymphoma (a less aggressive subset of non-Hodgkin lymphoma).[3]
[R]-CHOEP modification[edit]
In order to develop more effective first-line chemotherapy regimen for aggressive lymphomas, some researchers tried to add (E)toposide to the standard [R]-CHOP regimen.[4]
There were also attempts to further improve the efficacy of the [R]-CHOEP regimen with escalating the chemotherapy doses. This mode was called [R]-High-CHOEP. However, it did not show more effectiveness than standard-dose [R]-CHOEP while adding more toxicity and cost.[5]
In order to try improving efficacy of the [R]-CHOEP, some researchers tried to escalate chemotherapy to very high doses, requiring autologic stem cell support in each cycle. Doses in that regimen were increased from cycle to cycle. This regimen was called [R]-MegaCHOEP. But again, such escalation seemed to not improve effectiveness while adding toxicity.[6]
Chop Community Garden
Drug | Standard [R]-CHOEP | [R]-High-CHOEP | [R]-Mega-CHOEP, cycle 1 | [R]-Mega-CHOEP, cycles 2 and 3 | [R]-Mega-CHOEP, cycle 4 (last) | Mode | Days |
---|---|---|---|---|---|---|---|
(R)ituximab | 375 mg/m2 | 375 mg/m2 | 375 mg/m2 | 375 mg/m2 | 375 mg/m2 | IV infusion | Day 1 |
(C)yclophosphamide | 750 mg/m2 | 1400 mg/m2 | 1500 mg/m2 | 4500 mg/m2 | 6000 mg/m2 | IV infusion | Day 1 |
(H)ydroxydaunorubicin | 50 mg/m2 | 65 mg/m2 | 70 mg/m2 | 70 mg/m2 | 70 mg/m2 | IV bolus | Day 1 |
(O)ncovin | 1.4 mg/m2 (max 2 mg) | 2 mg | 2 mg | 2 mg | 2 mg | IV bolus | Day 1 |
(E)toposide | 100 mg/m2 | 175 mg/m2 | 600 mg/m2 | 960 mg/m2 | 1480 mg/m2 | IV infusion | Days 1-3 |
(P)rednisone or (P)rednisolone | 40 mg/m2 | 100 mg | 500 mg | 500 mg | 500 mg | PO qd | Days 1-5 |
Chopp Computer
See also[edit]
Chop Commute Times
References[edit]
- ^Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005). 'Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas'. N Engl J Med. 353 (10): 988–98. doi:10.1056/NEJMoa050078. PMID16148284.
- ^Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993). 'Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma'. N Engl J Med. 328 (14): 1002–6. doi:10.1056/NEJM199304083281404. PMID7680764.
- ^'Nordic Protocol (Maxi-CHOP and High Dose Cytarabine) for Mantle Cell Lymphoma (MCL)'(PDF). Archived from the original(PDF) on 2014-09-11. Retrieved 2014-09-11.
- ^http://www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/chemotherapy/combinationregimen/r-chop.aspx
- ^New Combo Replaces CHOP for Lymphoma. Dec 2012
- ^Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
- ^Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin’s lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)
- ^Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)